Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Open Access
- 11 April 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (8) , 1908-1919
Abstract
Vaso-occlusive episodes (VOC) or pain crises are the most common indications for hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Elimination of pain crisis after HCT is an important patient-centered outcome and may improve understanding of the natural history of pain syndromes in SCD. We examined deidentified records of 763 patients followed-up for a median of 36.7 months (range, 0.3-168.6 months), with 69.6% patient's age 10 years at HCT (range, 11-17 years; OR, 9.43; 95% CI, 3.20-27.79; P < .0001), in age ≥18 years (OR, 16.62; 95% CI, 5.85-47.16; P < .0001), in those with history of pain crisis 2 years before HCT (OR, 13.16; 95% CI, 4.08-42.42; P < .0001), alternate donors (haploidentical [OR, 4.80; 95% CI, 2.48-9.31; P < .0001], unrelated matched [OR, 2.71; 95% CI, 1.23-5.97; P = .0132], and mismatched unrelated [OR, 3.19; 95% CI, 1.44-7.05; P = .0041], and those with GF (n = 41 [5.37%]; OR, 7.15; 95% CI, 4.20-12.18; P < .0001). Pain crisis was less frequent with KPS of ≥90 (OR, 0.31; 95% CI, 0.18-0.55; P < .0001). Multivariable logistic regression models confirmed age at HCT, KPS, graft type, donor type, history of VOC 2 years before HCT, and GF as independent predictors of pain crisis after HCT and generated predictive models and nomograms for pain crisis after HCT for SCD, which can support shared decision making.Keywords
This publication has 21 references indexed in Scilit:
- Pain and opioid use after reversal of sickle cell disease following HLA‐matched sibling haematopoietic stem cell transplantBritish Journal of Haematology, 2018
- Chronic Opioid Therapy and Central Sensitization in Sickle Cell DiseaseAmerican Journal of Preventive Medicine, 2016
- An Evaluation of Central Sensitization in Patients With Sickle Cell DiseaseThe Journal of Pain, 2016
- A Standard Nonmyeloablative Transplantation Regimen for Adults with Sickle Cell Disease: Are We There Yet?Transplantation and Cellular Therapy, 2016
- Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell DiseaseTransplantation and Cellular Therapy, 2016
- Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell PhenotypeJAMA, 2014
- Thinking beyond sickling to better understand pain in sickle cell diseaseEuropean Journal of Haematology, 2014
- Understanding pain and improving management of sickle cell disease: the PiSCES study.2005
- Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions.1997
- Bone-Marrow Transplantation in a Patient with Sickle-Cell AnemiaNew England Journal of Medicine, 1984